Patient Death In New Alzheimer’s Drug Aduhelm
by Richard Kuehn on 11/11/21
There was
much excitement when the FDA approved a new drug called Aduhelm to treat
patients with Alzheimer’s disease.
Although there was some debate over its efficacy, the fact that there
have been no new drugs brought to market to treat this horrible disease in decades
had some filled with hope. However,
Biogen Inc., the pharmaceutical company who makes the drug, admitted this week
that there was one death linked to Aduhelm.
The company announced that a 75-year old who took the drug was
hospitalized and diagnosed with swelling in the brain before dying. It’s unclear that the brain swelling was
linked to the drug, however, there is sure to be an investigation due to the
fact that brain swelling, also known as ARIA-E, was cited as one of the most
common side effects during testing of the drug.
https://www.wsj.com/articles/biogen-investigates-death-of-aduhelm-patient-11636479862